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Background: Measurement of serum creatinine (sCr) and urea nitrogen fail to detect decreased
renal function in many hyperthyroid cats because of low muscle mass and glomerular hyperfil-
tration of affected cats. Serum symmetric dimethylarginine (sSDMA) is an earlier and more sen-
sitive renal biomarker than sCr.
Objective: Evaluate sSDMA as a biomarker of renal function in hyperthyroid cats before
(T0) and 1 month after (T1) radioiodine (131I) treatment.
Animals: Forty-seven client-owned hyperthyroid nonazotemic cats were evaluated at T0 and T1.
Methods: A prospective study in which sCr and sSDMA concentrations were determined in
47 hyperthyroid cats at T0 and at T1. Glomerular filtration rate (GFR) was estimated at T0 and
T1 in 10 of these 47 cats using plasma exogenous creatinine clearance test.
Results: Serum SDMA was elevated (>14 μg/dL) in 6 of 47 cats at T0 and normalized after treat-
ment in 4 of those cats. All cats remained nonazotemic after treatment. In 10 cats in which GFR
was measured, correlation between GFR and sSDMA was low and not significant (τb = −0.35,
P = .17 at T0 and τb = −.22, P = .41 at T1), whereas correlation between GFR and sCr was
moderate and significant (τb = −0.52, P < .05 at T0 and τb = −.53, P = <.05 at T1).
Conclusions and Clinical Importance: Careful interpretation of mildly increased sSDMA with
normal sCr in hyperthyroid cats is warranted as sSDMA values might normalize after resolution of
hyperthyroidism in some cats. In this population of hyperthyroid cats, sSDMA was poorly
correlated with GFR.
KEYWORDS
131I, chronic kidney disease, CKD, feline, GFR, glomerular filtration rate, hyperthyroidism,
symmetric dimethylarginine
1 | INTRODUCTION
Hyperthyroidism and chronic kidney disease (CKD) are common disor-
ders in aged cats and frequently occur together. Glomerular hyperfil-
tration and loss of muscle mass in cats with hyperthyroidism often
lead to decreased serum creatinine (sCr) which can hamper the diag-
nosis of CKD in these patients. Azotemia is observed in 10% of hyper-
thyroid cats at diagnosis, and 15%-60% cats develop renal azotemia
after treatment.1–4 Early identification of decreased renal function in
hyperthyroid cats could contribute to the best treatment choice of
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hyperthyroidism and allow earlier management of CKD. Closer follow-
up of radioiodine (131I)-treated cats with early CKD could prevent
potential long-standing iatrogenic hypothyroidism which can contrib-
ute to exacerbation of azotemia and reduced survival time.5
Routinely used renal biomarkers, sCr and serum urea, are neither
sensitive nor specific biomarkers to detect renal dysfunction. The
influence of muscle mass and analytic variability of sCr leads to its
poor sensitivity.6,7 Glomerular filtration rate (GFR) is considered the
gold standard to evaluate renal function but is usually described as
time demanding and stressful for cats.8 Glomerular filtration rate lim-
ited sampling strategies were developed to diminish these difficulties.9
Despite that, GFR is still not routinely used in clinical settings. There is
a need for early renal markers not influenced by nonrenal factors,
especially in often poorly muscled hyperthyroid cats.
Symmetric dimethylarginine (SDMA) is a byproduct of protein
methylation, is minimally protein bound, and is freely filtered through
the glomerulus. In people, more than 90% of SDMA is eliminated by
renal clearance.10 Symmetric dimethylarginine closely correlates with
GFR in healthy elderly cats and cats with CKD.11–13 Sensitivity and
specificity of SDMA to identify decreased renal function in cats with
CKD is 100% and 91%, respectively.13 Furthermore, in healthy Bea-
gles, a reduction of lean body mass can lower sCr concentration and
therefore overestimate GFR, whereas SDMA is not influenced by lean
body mass changes.14 There is a positive correlation of sCr with lean
body mass but no correlation of SDMA with lean body mass in healthy
elderly cats suggesting that sCr concentration is more affected by age
and lean body mass than SDMA.12 Based on these characteristics,
SDMA is expected to be a better renal marker than sCr in hyperthy-
roid cats. Symmetric dimethylarginine has higher sensitivity to predict
renal azotemia than sCr in hyperthyroid cats although sensitivity of
SDMA is as low as 33%.15 Further evaluation of SDMA in hyperthy-
roid cats is needed.
The objective of this study was to evaluate SDMA as a renal bio-
marker in hyperthyroid cats along with GFR and sCr before and
1 month after 131I treatment.
2 | MATERIALS AND METHODS
2.1 | Animals
Fifty client-owned hyperthyroid cats treated with 131I at the Small
Animal Department of Ghent University were prospectively enrolled
in the study. Approval from the Local Ethical Committee of Ghent
University (EC 2015/67) was obtained, and owners signed an
informed consent. Inclusion criteria were diagnosis of hyperthyroidism
based on clinical signs, increased serum total thyroxine (TT4) concen-
tration, and increased pertechnetate uptake in one or both thyroid
glands or ectopic thyroid tissue on scintigraphic scan. Exclusion
criteria were azotemia (sCr > 2.3 mg/dL, reference interval [RI] of
IDEXX Laboratories, Inc, Westbrook, Maine), any clinically relevant
systemic disease other than hyperthyroidism, and use of any medica-
tion within 2 weeks before enrolling in the study except for antithy-
roid medication. Antithyroid medication was stopped 10 days before
131I treatment. Cats had to have a consistent diet at least 1 month
before and during the study. Cats on raw meat diet were excluded.
Cats were treated with an individually adapted dose of 131I injected IV
(mean dose 142.6 MBq; range: 67.7-455.1 MBq). The dose was based
on the severity of the clinical signs, serum TT4, and thyroid-to-salivary
gland ratio as determined on the pertechnetate scan.16
2.2 | Sampling
Cats were evaluated shortly (4-48 hours) before (T0) and 1 month after
(T1) 131I treatment. Full health screening was performed at T0 including
medical history, physical examination, systolic blood pressure (BP), CBC,
biochemistry profile, urinalysis, urine culture, abdominal ultrasonogra-
phy, standard 2-view thoracic radiographs (lateral and ventrodorsal
projections), and echocardiography.17 At both time points (T0 and T1),
body weight (BW), body condition score (BCS) (9-point scale), muscle
condition score (MCS), BP, serum TT4, serum thyroid-stimulating hor-
mone (TSH), sCr, serum urea, sSDMA, GFR, urine specific gravity (USG),
and urinary protein : creatinine ratio (UPC) were assessed. A noninvasive
BP was measured using Doppler ultrasonic technique following the
ACVIM consensus.18 All blood samples were centrifuged within
30 minutes after collection, serum separated and stored at 4C until
sent to commercial laboratory within 24 hours from collection. Samples
for TSH were stored at −80C and sent for batch analysis at the end
of the study. Serum creatinine was determined by an enzymatic
colorimetric method, Jaffé's reaction using picrate at alkaline pH
(Beckman Coulter, Inc, Brea, California), and azotemia was defined as
sCr > 2.3 mg/dL based on upper limit of sCr RI established by IDEXX
Laboratories. Serum SDMA was determined using a commercially avail-
able high-throughput immunoassay (IDEXX SDMA Test), and sSDMA
RI ≤ 14 μg/dL) was established by IDEXX Laboratories.19 Serum TT4
concentration was measured on an automated biochemistry analyzer
using a homogenous enzyme immunoassay (DRI T4 assay; Microgenics
Corporation, Freemont, California). Serum TSH was determined using
canine TSH chemiluminescent enzyme immunoassay (Immulite Canine
TSH; Siemens Healthcare Diagnostics Products, Tarrytown, New York).
2.3 | Glomerular filtration rate
Exogenous plasma creatinine clearance testing was offered to owners
and performed in 10 of 47 cats at T0 and T1 using protocol previously
established by our research group.20 The number of blood samplings
in the protocol was adapted based on a published limited sampling
strategy for research purposes.9 More specifically, catheter was
placed in the cephalic vein, baseline blood sample was obtained, and
40 mg/kg of creatinine were injected IV. Blood samples were col-
lected into an EDTA tube 5, 30, 60, 120, 180, 360, and 600 minutes
after creatinine injection. All samples were centrifuged within 1 hour
from collection, and separated plasma was stored at 4C until sent to
the commercial laboratory the next day. Plasma creatinine was deter-
mined using enzymatic colorimetry as described above. Glomerular fil-
tration rate was estimated using a noncompartmental approach with
extrapolation to infinity. The clearance was equal to the dose divided
by the area of the concentration versus time curve. The borderline
low GFR cutoff value was defined as 1.9 mL/min/kg and the low GFR
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cutoff value as 1.4 mL/min/kg based on previous data from our
research group.9
2.4 | Thyroid status
One month after treatment with 131I, cats were classified as euthyroid
if serum TT4 concentration was normal or below RI (0.8-4.7 μg/dL)
with normal serum TSH concentration (≤0.3 ng/mL), as hypothyroid if
serum TT4 concentration was below RI with increased serum TSH
concentration (>0.3 ng/mL), or as subclinically hypothyroid if serum
TT4 concentration was normal with increased serum TSH concentra-
tion (>0.3 ng/mL), and as hyperthyroid if serum TT4 was above RI
with TSH <0.3 ng/mL.5,21
2.5 | Statistical analysis
The effect of the treatment was assessed by the signed rank test with
cat as blocking factor, as not all response variables could be assumed
to be normally distributed. Kendall's τ correlation coefficients were
derived to investigate the correlation between different response vari-
ables. With 47 cats, the power for a paired test to prove a difference
in SDMA between T0 and T1 at the 5% significance level, assuming
an SD equal to 4.8 and a true difference of 2 is equal to 80%.
3 | RESULTS
3.1 | Animals
Fifty client-owned hyperthyroid cats treated with 131I were enrolled
in the study. Three cats were excluded because of owner noncompli-
ance (n = 1), congestive heart failure (n = 1), and thyroid carcinoma
with pulmonary metastasis (n = 1). Of the 47 included cats, 22 were
male neutered, 24 female spayed, and 1 female intact. Represented
breeds included 44 domestic short-hair or long-hair cats, 1 British
Shorthair, 1 Norwegian Forest Cat, and 1 Chartreux. Median age was
13 years (range 7-16 years). Selected clinical and laboratory variables
of the total group are summarized in Table 1. Twenty-one of 47 (45%)
patients were previously treated for hyperthyroidism with methima-
zole (Felimazole; Dechtra Veterinary Products, Overland Park, United
Kingdom) (n = 17), with carbimazole (Teva, Haarlem, the Netherlands)
(n = 1), with combination of unilateral thyroidectomy and methima-
zole (Dechtra Veterinary Products) (n = 1) or with Hill's Y/D diet (Hill's
Pet Nutrition, Inc, Topeka, Kansas) (n = 2). Body weight and BCS
significantly increased after treatment (P < .001). Muscle condition
score overall significantly improved after treatment (P < .001); MCS
improved in 28 cats (60%), remained stable in 17 cats (36%), and
worsened in 2 cats (4%) after treatment. The 1 cat that had persistent
severe muscle loss remained hyperthyroid after treatment.
3.2 | Serum renal biomarkers, USG and UPC
Serum creatinine concentration significantly increased 1 month after 131I
treatment compared to T0 (Table 1). Serum creatinine increased in
44 cats (94%), decreased in 2 cats (4%) and remained unchanged in 1 cat
(2%) after treatment (Figure 1). Despite significant sCr increase 1 month
after treatment, all 47 cats remained nonazotemic (sCr <2.3 mg/dL) dur-
ing the study period. The serum urea concentration significantly
increased after treatment. There was no significant difference between
sSDMA at T0 and T1 (Table 1). Serum SDMA increased in 19 cats (40%),
decreased in 23 cats (49%), and remained unchanged in 5 cats (11%)
after 131I treatment compared to T0 (Figure 1). Serum SDMA was above
RI in 6 cats at T0 and in 5 cats at T1. Serum SDMA normalized after 131I
treatment in 4 of the 6 cats with increased concentrations before treat-
ment. Serum SDMA exceeded 14 μg/dL at T1 in 3 cats that had normal
sSDMA at T0. The correlation between sCr and sSDMA was low at both
time points (τb = 0.31, P < .01 at T0 and τb = 0.29, P < .01 at T1). The
USG and UPC significantly decreased after treatment. Urine specific
gravity was <1.035 in 9 cats at T0 and in 20 cats at T1. Three of 6 cats
TABLE 1 Selected clinical and laboratory variables of total group (n = 47) before (T0) and 1 month after (T1) radioiodine treatment provided as
median (range)
Variables (RI + units) T0 T1
Median of difference between
T1 and T0 (range) P
Age (years) 13 (7–16)
BW (kg) 3.8 (1.5-6.5) 4.2 (2.0-6.4) 0.2 (−0.3 to 1.1) <.001
BCS 4/9 (2-8 /9) 5/9 (2–8 /9) 0 (−1 to 2) <.001
MCS Normal; n = 7 (15%) Normal; n = 22 (47%) Improved <.001
Mild loss; n = 20 (43%) Mild loss; n = 18 (38%)
Moderate loss; n = 15 (32%) Moderate loss; n = 6 (13%)
Severe loss; n = 5 (10%) Severe loss; n = 1 (2%)
BP (mm Hg) 160 (125-225) 165 (125-220) 0 (−70 to 50) .67
Serum TT4 (0.8-4.7 μg/dL) 8.3 (2.2->13) 0.9 (<0.7-8) −6.7 (<−12.3 to −0.6) <.001
Serum TSH (<0.3 ng/mL) <0.03 (<0.03-0.04) 0.09 (<0.03-0.95) −0.05 (0 to 0.92) <.001
Serum creatinine (0.9-2.3 mg/dL) 0.67 (0.39-1.55) 1.23 (0.39-2) 0.52 (−0.57 to 1.17) <.001
Serum urea (16-38 mg/dL) 22.7 (12.6-53.5) 28.0 (17.4-58.8) 4.2 (−6.2 to 20) <.001
Serum SDMA (0-14 μg/dL) 10 (1-18) 11 (6-20) 0.0 (−7 to 19) .61
USG >1.050 (1.016->1.050) 1.042 (1.013->1.050) −0.008 (−0.037 to 0.010) <.001
UPC (<0.33) 0.5 (0.2-2.4) 0.2 (0.1-0.82) −0.3 (−2.1 to 0.12) <.001
Abbreviations: BCS, body condition score; BP, blood pressure; BW, body weight; MCS, muscle condition score; RI, reference interval; SDMA, symmetric
dimethylarginine; TSH, serum thyroid-stimulating hormone; TT4, serum total thyroxine; UPC, urinary protein : creatinine ratio; USG, urine specific gravity.
BURESOVA ET AL. 3
with increased sSDMA at T0 had also USG < 1.035 and 2 of 4 cats in
which sSDMA normalized after treatment had USG < 1.035. Four of
5 cats with increased sSDMA at T1 had also USG < 1.035.
3.3 | Thyroid status
Total serum thyroxine was significantly lower and serum TSH was sig-
nificantly higher at T1 compared to T0 (Table 1). One month after 131I
treatment, 1 cat (2%) remained hyperthyroid, 41 cats (87.5%) were
euthyroid, 3 cats (6.5%) were subclinically hypothyroid, and 1 cat (2%)
was hypothyroid. Unknown thyroid status was assigned to 1 cat (2%)
in which serum TSH concentrations was missing and TT4 concentra-
tion was below RI. All subclinically hypothyroid and hypothyroid cats
had normal sCr and sSDMA at T0 and T1 and 2 cats had USG < 1.035.
Serum TT4 and creatinine showed moderate and significant negative
correlation at T0 (τb = −0.39, P < .001) and low and not significant
negative correlation at T1 (τb = 0.09, P = .4). Serum TT4 and SDMA
showed low and not significant negative correlation at both time points
(τb = −0.05, P = .61 at T0 and τb = −0.13, P = .26 at T1). Correlation
between serum TSH and sCr was low and not significant at T0 but mod-
erate and significant at T1 (τb = 0.1, P = .16 at T0 and τb = 0.52,
P < .001 at T1). Correlation of serum TSH and sSDMA was low and not
significant at both time points (τb = 0.04, P = .78 at T0 and τb = 0.15,
P = .18 at T1).
There was no significant difference in sCr, sSDMA, serum urea,
USG, or BW between the group of euthyroid cats and the group of
subclinically hypothyroid and hypothyroid cats.
3.4 | Glomerular filtration rate
Selected clinical and laboratory variables of the subgroup of cats with
GFR are summarized in Table 2. Four of ten cats with GFR (40%) were
pretreated with antithyroid medication compared to 45% pretreated
cats in the total population. When the subgroup of cats with GFR was
compared with the total population of cats for age, BW, sCr, sSDMA,
TT4, and BP, no statistical significant difference was found at T0 and
T1. Urine specific gravity was significantly higher in GFR subgroup
compared to the total population at both time points.
Glomerular filtration rate was measured at T0 and T1 in 10 of
47 included cats. Glomerular filtration rate significantly decreased
after treatment (Table 2; Figure 1). None of the cats had low or bor-
derline low GFR before treatment. At T1, 1 cat had low GFR and 1 cat
borderline low GFR. The cat with borderline low GFR was euthyroid
and had increased sSDMA at T1. The cat with low GFR was euthyroid
and had normal sSDMA at T1. Serum SDMA after treatment was
normal, and USG was ≥1.035 at T0 in both these cats and USG was
<1.035 at T1 in 1 of them. Correlation between GFR and sSDMA
(n = 10) was low and not significant at both times (τb = −0.35,
P = .17 at T0 and τb = −0.22, P = .41 at T1), whereas correlation
between GFR and sCr was moderate and significant in both times
(τb = −0.52, P < .05 at T0 and τb = −0.53, P = <.05 at T1).
4 | DISCUSSION
This study evaluates SDMA in conjunction with sCr and GFR in hyper-
thyroid cats treated with 131I. We found a moderate correlation of sCr
with GFR and a low correlation of sSDMA with GFR and with sCr.
Serum SDMA did not significantly change after treatment which is in
contrast to significant increase of sCr and significant decrease of
GFR after treatment. Furthermore, mildly increased sSDMA before
treatment normalized in some cats after 131I treatment. Although
based on low numbers, sCr and sSDMA before treatment did not
predict abnormally low GFR after treatment.
The correlations of sSDMA with GFR and sSDMA with sCr were
low and not significant at both times (T0 and T1). This is in contrast to
high and significant correlation of SDMA with GFR and SDMA with
sCr in previous studies evaluating healthy elderly and CKD cats.11–13
Although GFR significantly decreased after treatment in all 10 cats,
there was no obvious pattern of sSDMA changes in our complete
study population (see Figure 1). This confirms the poor correlation of
GFR with SDMA in our hyperthyroid cats. As expected, GFR and sCr
correlation in our population was only moderate because sCr is known
FIGURE 1 Serum creatinine, serum SDMA, and GFR before (T0) and
1 month after (T1) radioiodine treatment. Dotted lines show upper limit
of reference interval for SDMA and creatinine and borderline low cutoff
value for GFR. GFR, glomerular filtration rate; SDMA, symmetric
dimethylarginine
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to be a poor renal marker in hyperthyroid cats. In a recent study,
hyperthyroid cats managed with controlled iodine diet showed higher
sSDMA correlation with GFR (r = 0.71, P = .04) than sCr with GFR
(0.55, P = .04), which is in contrast with the present results. In that
study, sCr significantly decreased and GFR did not change over a
period of 6 months on controlled iodine diet; sSDMA also did not
change over time. Interestingly, only 5 of 15 cats in that study
achieved euthyroidism based on serum TT4 concentrations, which
could explain why GFR did not decrease and sCr did not increase as
expected after resolving hyperthyroidism.22
Data of subgroup of cats in which GFR (n = 10) was measured
show that neither sCr nor sSDMA perform well as renal biomarkers in
hyperthyroid cats. Glomerular hyperfiltration in hyperthyroidism leads
to increased GFR which may influence also renal filtration of SDMA.
This could explain why sSDMA before treatment did not predict low
GFR after treatment in our study population. Serum SDMA after
treatment was above RI in 1 of 2 cats with abnormally low GFR. These
2 cats were euthyroid after treatment and therefore hypothyroidism
causing decreased GFR was excluded. Serum SDMA sensitivity (33.3%)
to predict azotemia after treatment of hyperthyroidism in cats is higher
than sCr sensitivity (11.9%).15 Nevertheless, these results indicate that
SDMA is still a poor predictor of after treatment azotemia.
Serum SDMA was increased before treatment in 6 cats (13%) of
our study population and normalized after treatment in 4 of them.
Only 1 of these 6 cats had GFR performed which was normal in both
times. Similarly in a recent study, SDMA normalized after 131I
treatment in 3 of 5 nonazotemic cats with increased pretreatment
SDMA.15 Furthermore, in a study of 19 methimazole treated
hyperthyroid cats, SDMA normalized after starting methimazole in
1 of 2 cats in which follow-up was available.23 Therefore, temporarily
mildly increased serum SDMA should be interpreted carefully while
evaluating pretreatment renal function in hyperthyroid cats. Close
follow-up of both renal markers (creatinine and SDMA) after treat-
ment is recommended to avoid misinterpretation.
There is a positive association of SDMA with increased thyroid
function in humans.24 Serum SDMA is a byproduct of protein
methylation, and protein metabolism is considerably changed in hyper-
thyroid cat. Therefore, we can speculate that hyperthyroidism might
influence SDMA concentration in cats. The production rate of SDMA in
the body is relatively stable, but protein breakdown could potentially
contribute to changes in serum concentration.7 Furthermore, SDMA is
freely filtered by the kidneys, but there is also hepatic clearance in peo-
ple.25 The extent of hepatic SDMA clearance and whether it changes in
hyperthyroidism is unknown in cats. Nevertheless, there was no corre-
lation between serum TT4 or serum TSH and SDMA in our study, which
is in agreement with a recent study in hyperthyroid cats showing also
very weak correlation of serum SDMA and TT4 concentrations.15
The present study showed expected evolution of sCr, serum urea,
and GFR, where sCr and serum urea significantly increased and GFR sig-
nificantly decreased after treatment of hyperthyroidism. Nevertheless,
none of the cats became azotemic after treatment. This is in contrast
with literature where 15%-60% of hyperthyroid cats become azotemic
after treatment.2–4 In our study, 45% of cats were previously treated
with antithyroid medication or with controlled iodine diet which might
have played a role in preselection of nonazotemic cats. Furthermore,
the increase of creatinine might have been hampered by incomplete
resolution of muscle mass loss 1 month after treatment in about a half
of the cats. Longer follow-up would be necessary to assess if some cats
would develop azotemia later. On the other hand, our study design was
based on previously published data of our research group showing that
renal function stabilizes 4 weeks after 131I treatment and there is no sig-
nificant decline in renal function later on.26 Based on the findings of that
study, we should be able to recognize cats with impaired renal function
1 month after treatment based on sCr levels. This reasoning is further
supported by another study showing that GFR significantly decreases
1 month after 131I treatment, but there is no further significant GFR
decrease between 1 and 6 months after treatment.27 In that study, cre-
atinine further increased between 1 and 6 months after treatment
which was most likely a result of muscle wasting resolution or prerenal
azotemia considering that GFR remained stable.27 Furthermore, long-
term follow-up could show development of CKD unrelated to resolu-
tion of hyperthyroidism. Up to 30% of previously healthy geriatric cats
TABLE 2 Selected clinical and laboratory variables of subgroup of cats with GFR performed (n = 10) before (T0) and 1 month after
(T1) radioiodine treatment provided as median (range)
Variables (RI + units) T0 T1
Median of difference
between T1 and T0 P
Age (years) 12.5 (8-15)
BW (kg) 4.0 (2.6-5.1) 4.2 (2.9-5.1) 0.3 (0-0.6) <.001
MCS Normal; n = 2 (20%) Normal; n = 7 (70%) Improved <.001
Mild loss; n = 4 (40%) Mild loss; n = 3 (30%)
Moderate loss; n = 3 (30%)
Severe loss; n = 1 (10%)
BP (mm Hg) 163 (140-225) 170 (125-200) 5 (−10 to 50) .67
Serum TT4 (0.8-4.7 μg/dL) 10 (4.8->13) 0.8 (<0.7-1.3) −8.9 (<−12.2 to −3.5) <.001
Serum creatinine (0.9-2.3 mg/dL) 0.66 (0.39-1) 1.21 (0.97-1.5) 0.54 (0.27 to 0.85) <.001
Serum SDMA (0–14 μg/dL) 9.5 (4-15) 11 (7-17) 2.5 (−5 to 8) .2
USG >1.050 (1.040->1.050) >1.050 (1.032->1.050) 0 (−0.008 to 0.010) .42
GFR (≥1.9 mL/min/kg) 3.65 (2.1-5) 2.15 (0.9-3.4) −1.7 (−2.2 to −0.1) .002
Abbreviations: BCS, body condition score; BP, blood pressure; BW, body weight; MCS, muscle condition score; RI, reference interval; SDMA, symmetric
dimethylarginine; TSH, serum thyroid-stimulating hormone; TT4, serum total thyroxine; UPC, urinary protein : creatinine ratio; USG, urine specific gravity.
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develop azotemia during 12-month follow-up.28 This further supports
that short-term follow-up should be suitable to evaluate kidney function
after treatment of hyperthyroidism. A possible explanation for lack of
azotemia after treatment in our study population might be the labora-
tory RI for sCr. Serum creatinine has a large biologic and analytic vari-
ability which often leads to overly wide RIs established by laboratories.7
Urinary protein : creatinine ratio significantly decreased after
treatment; this is an expected evolution as glomerular hyperfiltration,
changes in glomerular barrier, as well as changes in tubular protein
management increase proteinuria in hyperthyroidism, and proteinuria
decreases quickly after resolution of hyperthyroidism in people.1
Urine specific gravity significantly decreased after treatment, and
more cats had USG <1.035 at T1 than at T0. Despite significant
decrease of USG, the median value remained above 1.035 after treat-
ment. Hyperthyroidism can lead to decreased ability to concentrate
urine without clinical significance.1 We would expect that cats with
normal kidney function would be able to concentrate urine after reso-
lution of hyperthyroidism. The decrease of USG might reflect early
kidney dysfunction or hypertension-induced diuresis.28–30
As expected, BW and BCS significantly increased and MCS signifi-
cantly improved in the majority of cats. Almost half of the cats had nor-
mal muscle mass already 1 month after 131I treatment. This is awaited
evolution after resolution of hyperthyroidism. Serum creatinine was sig-
nificantly higher in cats with none to mild muscle mass loss compared
to cats with moderate to severe muscle mass loss before treatment but
this difference was insignificant after treatment (Table 3). These results
are in agreement with the well-known fact that sCr is influenced by
muscle mass and sCr might be lower in cats with muscle wasting such
as cats with hyperthyroidism or CKD as well as elderly cats.7 There was
no significant difference in SDMA in cats with none to mild muscle
mass loss when compared to cats with moderate to severe muscle mass
loss. This finding is not surprising as in healthy elderly cats and in
healthy Beagles, SDMA is not influenced by lean body mass.12,14
The majority of cats in our study were euthyroid 1 month after
131I treatment, only 9% cats were subclinically hypothyroid or hypo-
thyroid. None of these hypothyroid cats needed to start thyroid hor-
mone supplementation 1 month after 131I treatment because neither
clinical signs of hypothyroidism nor azotemia were present. Percent-
ages of hypothyroidism and transient hypothyroidism after 131I treat-
ment vary in the literature from 5% incidence of iatrogenic
hypothyroidism in older studies to 30%, 79%, and 83% in later stud-
ies.5,27,31,32 There is a lower incidence of hypothyroidism with low-
dose (2 mCi) compared to standard-dose (4 mCi) 131I treatment with
no significant difference of persistent hyperthyroidism between both
groups.21 Despite using mean 131I dose of 142.6 MBq (3.85 mCi), the
incidence of hypothyroidism was low (9%) in the present study. This
might be because of the short-term follow-up of our population, con-
sidering that iatrogenic hypothyroidism might develop up to
6-12 months after 131I treatment. On the other hand, it is also possible
that the 4 hypothyroid cats in our study were suffering from transient
hypothyroidism which might have resolved in the subsequent months.
Furthermore, different cutoff values of TSH to diagnose hypothyroid-
ism varying from 0.15 to 0.30 ng/mL were used in previous stud-
ies.5,21 The RI for euthyroid cats was recently established for the TSH
assay specifically used in our study (Immulite Canine TSH).21 We used
the upper limit of this RI (0.3 ng/mL) as a cutoff value to determine
hypothyroidism. Using this cut-off value led to diagnosis of a lower
number of hypothyroid cats than if we would have used previously
reported lower cutoff values. Further studies are needed to establish
appropriate cutoff value for diagnosing hypothyroidism in cats.
Previous studies used liquid chromatography-mass spectroscopy
(LC-MS) which is considered a gold standard technique to measure
sSDMA concentrations. In our study, the sSDMA concentrations were
measured using a validated immunoassay IDEXX SDMA Test (IDEXX
Laboratories, Inc).19 This assay is commercially available and afford-
able compared to the LC-MS and consequently more convenient for
use in clinics. GFR was performed using plasma exogenous creatinine
clearance test as previously described by our research group.9,20
Glomerular filtration rate RI has to be established for each clearance
protocol separately, as there is a high variation depending on the
method of GFR measuring, clearance markers, and study population.
We used cutoff values for borderline low and low GFR defined by our
research group as 1.9 mL/min/kg and 1.4 mL/min/kg, respectively.9
The main limitations of our study were the relatively low number
of cats and the absence of azotemia after 131I treatment both of
which precluded assessment of predictive value for development of
renal azotemia after treatment.
In conclusion, careful interpretation of mildly increased sSDMA
with normal sCr in hyperthyroid cats is warranted considering that
sSDMA concentrations might return back to RI after resolution of
hyperthyroidism in some cats. Additionally, our study shows lower
correlation between sSDMA and GFR compared to correlation
between sCr and GFR in hyperthyroid cats treated with 131I.
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TABLE 3 Median (range) serum creatinine and SDMA in cats with none to mild muscle atrophy compared to cats with moderate to severe
muscle atrophy
Variables (units)
None to mild
muscle atrophy
Moderate to severe
muscle atrophy
Difference between
groups: P-value
Serum creatinine at T0 (mg/dL) 0.81 (0.54-1.55) 0.64 (0.38-1.04) .01
Serum SDMA at T0 (μg/dL) 10.78 (4.00-18.00) 9.75 (1.00-18.00) .3
Serum creatinine at T1 (mg/dL) 1.26 (0.69-2.01) 1.02 (0.38-1.70) .14
Serum SDMA at T1 (μg/dL) 10.87 (6.00-19.00) 11.33 (6.00-20.00) .74
Abbreviations: SDMA, symmetric dimethylarginine; T0, time before radioiodine treatment; T1, time 1 month after radioiodine treatment.
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